{"disease":{"id":"acute-lymphoblastic-leukemia-pediatric","name":"acute lymphoblastic leukemia pediatric"},"drugs":{"marketed":[{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03643276","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Martin Schrappe","has_results":false},{"nct_id":"NCT06763302","title":"NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1220,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT05973032","title":"MRD Detection by NGS in Pediatric B-ALL","phase":"","overall_status":"COMPLETED","enrollment_count":430,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT06559345","title":"A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT04400071","title":"Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT06564493","title":"A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT06581081","title":"Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05334823","title":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06074666","title":"Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05622682","title":"Vaccine Immune Recovery After Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":true},{"nct_id":"NCT04228393","title":"The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Wei Zhao","has_results":false},{"nct_id":"NCT05029531","title":"Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04770922","title":"Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Cipherome, Inc.","has_results":false},{"nct_id":"NCT07374315","title":"Weight Gain in Pediatric Leukemia Survivors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06257394","title":"Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Hyoung Jin Kang","has_results":false},{"nct_id":"NCT06525116","title":"MRD Detection by NGS in Pediatric T-ALL","phase":"","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT03676504","title":"Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT04881240","title":"Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05809284","title":"Determining the Mechanisms of Loss of CAR T Cell Persistence","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05032716","title":"EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04472286","title":"Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT05045443","title":"Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT05939791","title":"Physical Exercise and Dairy Probiotics in Childhood Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Comenius University","has_results":false},{"nct_id":"NCT06334835","title":"Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"IRCCS SYNLAB SDN","has_results":false},{"nct_id":"NCT06421155","title":"Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia","phase":"NA","overall_status":"SUSPENDED","enrollment_count":20,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06866873","title":"CD-19 CAR-T Cell for Pediatric ALL or Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Hong Kong Children's Hospital","has_results":false},{"nct_id":"NCT03467256","title":"CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT03705507","title":"International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT03964259","title":"Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT04088864","title":"CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT04888468","title":"Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT00439296","title":"ABT-751 With Chemotherapy for Relapsed Pediatric ALL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Therapeutic Advances in Childhood Leukemia Consortium","has_results":true},{"nct_id":"NCT04049383","title":"CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT04996160","title":"Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Tanja Andrea Gruber","has_results":false},{"nct_id":"NCT04325841","title":"Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Beijing Boren Hospital","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}